阿可替尼治疗初治慢性淋巴细胞白血病
在单臂1/2期ACE-CL-001试验的初治CLL队列中,99例因合并症不适合化疗的成人患者接受阿可替尼单药治疗。中位随访53个月,总缓解率97%,48个月缓解持续率97%,38%报告严重不良事件;持久的疗效与长期安全性支持其用于有症状的初治CLL患者。
要点
- 初治CLL患者阿可替尼单药总缓解率97%,48个月缓解持续率97%。
- 因两日给药BTK占据率更优,全部患者转为100 mg每日两次。
- ≥3级特别关注事件:感染15%、高血压11%、出血3%、房颤2%。
核心结论
- 阿可替尼在初治有症状CLL中显示持久疗效与长期安全性,支持其用于临床管理。
研究设计与样本
- 单臂1/2期试验ACE-CL-001的初治CLL队列,纳入99例拒绝化疗或合并症不适合化疗的成人患者。
主要发现
- 中位随访53个月,85例仍在治疗,14例停药,主要因不良事件(6例)或疾病进展(3例)。
- 总缓解率97%(部分缓解90%,完全缓解7%),各预后亚组结果相似。
- 中位缓解持续时间未达到,48个月缓解持续率97%(95%CI 90-99)。
- 38例(38%)报告严重不良事件;6例(6%)因第二原发癌(4例)和感染(2例)停药。
- ≥3级特别关注事件包括感染15%、高血压11%、出血事件3%、心房颤动2%。
关键数值与推荐
- 阿可替尼口服200 mg每日一次或100 mg每日两次,直至进展或不耐受。
- 因每日两次给药改善BTK谷浓度占据率,全部患者转为100 mg每日两次。
- 患者中位年龄64岁,47%为Rai III/IV期,57例(62%)IgHV未突变,12例(18%)存在TP53异常。
临床怎么用
- 对于拒绝化疗或合并症不适合化疗的有症状初治CLL患者,可考虑阿可替尼单药治疗。
- 治疗期间需监测感染、高血压、出血及心房颤动等特别关注不良事件。
局限性
- 单臂1/2期试验设计,无随机对照,样本量99例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acalabrutinib has demonstrated significant efficacy and safety in relapsed chronic lymphocytic leukemia (CLL). Efficacy and safety of acalabrutinib monotherapy were evaluated in a treatment-naive CLL cohort of a single-arm phase 1/2 trial (ACE-CL-001). Adults were eligible for enrollment if chemotherapy was declined or deemed inappropriate due to comorbidities (N = 99). Patients had a median age of 64 years and 47% had Rai stage III/IV disease. Acalabrutinib was administered orally 200 mg once daily, or 100 mg twice daily until progression or intolerance. A total of 99 patients were treated; 57 (62%) had unmutated immunoglobulin heavy-chain variable gene, and 12 (18%) had TP53 aberrations. After median follow-up of 53 months, 85 patients remain on treatment; 14 discontinued treatment, mostly because of adverse events (AEs) (n = 6) or disease progression (n = 3). Overall response rate was 97% (90% partial response; 7% complete response), with similar outcomes among all prognostic subgroups. Because of improved trough BTK occupancy with twice-daily dosing, all patients were transitioned to 100 mg twice daily. Median duration of response (DOR) was not reached; 48-month DOR rate was 97% (95% confidence interval, 90-99). Serious AEs were reported in 38 patients (38%). AEs required discontinuation in 6 patients (6%) because of second primary cancers (n = 4) and infection (n = 2). Grade ≥3 events of special interest included infection (15%), hypertension (11%), bleeding events (3%), and atrial fibrillation (2%). Durable efficacy and long-term safety of acalabrutinib in this trial support its use in clinical management of symptomatic, untreated patients with CLL.
引用
- Byrd JC, Woyach JA, Furman RR, et al. Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood. 2021. PMID: 33786588. doi:10.1182/blood.2020009617
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。